Lower extremity arterial disease (LEAD) refers to the stenosis or occlusion of lower limb arteries caused by atherosclerotic plaque formation. It is estimated that approximately 237 million people worldwide, aged 25 and above, suffer from LEAD. In China, there are around 45.3 million LEAD patients, imposing a significant disease burden. Endovascular revascularization is the preferred treatment method for alleviating lower limb ischemic symptoms in LEAD patients with poor response to conservative therapy. However, due to reactions such as intimal hyperplasia after stent implantation, the mid- to long-term primary patency rates of endovascular revascularization remain inferior to open surgery, with a higher rate of reintervention. As a novel alternative treatment for the permanent metallic stent implantation, bioresorbable stents (BRS) are stents made from polymers or metal materials that can gradually decompose, degrade and eventually be completely eliminated from the body. After BRS implantation, temporary wall support is provided to the narrowed vascular segment, ideally degrading completely after vascular remodeling to restore physiological vasomotor activity and endothelial function. BRS holds the potential to avoid long-term complications such as in-stent restenosis, thereby further improving the efficacy of endovascular revascularization for LEAD. Currently, BRS such as REMEDY, ABSORB, and AMS have been used in the treatment of LEAD. REMEDY stent treatment for occlusive lesions of lower limb arteries shows suboptimal efficacy, with no apparent advantage over endarterectomy and nitinol stent implantation in treating stenotic lesions. ABSORB demonstrates a high 1-year patency rate for infrapopliteal lesions and a lower rate of target lesion reintervention. In comparison to percutaneous balloon angioplasty, AMS stent implantation has a significantly lower primary patency rate at six months and fails to meet efficacy evaluation criteria. Moreover, there is currently no high-quality recommendations of evidence-based medicine to guide anti-thrombotic treatment after BRS implantation in LEAD patients. In the future, efforts should be directed towards developing the next generation of BRS with superior material properties and optimal structural design. These advancements should be integrated with various endovascular treatment modalities for LEAD to effectively improve the quality of medical care for LEAD patients.